tailieunhanh - báo cáo khoa học: "The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1 | Usmani et al. Journal of Hematology Oncology 2010 3 40 http content 3 1 40 JOURNAL OF HEMATOLOGY ONCOLOGY RESEARCH Open Access The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1 c x x u 7 I I r x I 1 D Í X I X X r I ì D X x x -X 2 r r x l-x r I I x l x I r r I r 3 ỉ I l x x I I I4 Saad Z Usmani Robert D Bona Gabriela Chiosis Zihai LI Abstract Background Heat shock protein 90 HSP90 inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies. The HSP90 family includes the cytosolic HSP90 HSP90AA1 the ER paralogue gp96 HSP90B1 and the mitochondrial member TRAP1 HSP90L . We evaluated the in vitro anti-tumor activity and mechanism of action of PU-H71 a novel purine scaffold HSP90 inhibitor in human multiple myeloma cell lines. Methods Multiple human myeloma cell lines including cells that are resistant to corticosteroids and bortezimab were treated with PU-H71 followed by analysis of cell viability cell cycle progression and apoptosis by flow cytometry and caspase 3 immunoblot. Induction of unfolded protein response was studied by XBP-1 s immunoblot. The role of gp96 was further assessed by small hairpin RNA knockdown of gp96 before treatment with PU-H71. Results PU-H71 has potent in vitro anti-myeloma activity in both drug-sensitive and drug-resistant cell lines. PU-H71 activates the unfolded protein response and induces caspase-dependent apoptosis. The stable gp96 knockdown human myeloma cell line was found to be more resistant to PU-H71 and other HSP90 inhibitors including 17-AAG and 17-DMAG even though these cells are more sensitive to conventional anti-myeloma drugs. Conclusion We conclude that PU-H71 is a promising drug for the treatment of myeloma. Our finding further suggests that PU-H71 and the geldanamycin analogues work in part by inhibiting the endoplasmic reticulum gp96 along with the cytosolic HSP90. Introduction Multiple

TÀI LIỆU LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.